CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2062 views | HTML 2018 views | ?
Yang Zhao1,2,*, Jing Peng1,*, Enlong Zhang1, Ning Jiang2, Jiang Li1, Qi Zhang1, Xuening Zhang1, Yuanjie Niu2
1Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
2Sex Hormone Research Center, Tianjin Institute of Urology, Tianjin 300211, China
*These authors have contributed equally to this work
Xuening Zhang, e-mail: [email protected]
Yuanjie Niu, e-mail: [email protected]
Keywords: cancer stem cell, tumor recurrence, tumor genesis, CD133, meta-analysis
Received: August 18, 2015 Accepted: December 08, 2015 Published: January 28, 2016
We performed a meta-analysis of CD133-related clinical data to investigate the role of cancer stem cells (CSCs) in the clinical outcomes of colorectal cancer (CRC) patients, analyzing the effectiveness of various therapeutic strategies and examining the validity of the CSC hypothesis. For 28 studies (4546 patients), the relative risk (RR) to survival outcomes associated with CD133+ CRCs were calculated using STATA 12.0 software. Pooled results showed that CD133High patients had poor 5-year overall survival (RR 0.713, 95% CI 0·616–0·826) and 5-year disease free survival (RR 0·707, 95% CI 0·602–0·831). Both associations were consistently observed across different races, research techniques and therapeutic strategies. In a subgroup receiving adjuvant therapy, CD133Low patients achieved significantly better survival than CD133High patients. The findings suggest that CD133 could serve as a predictive marker of poor prognosis and treatment failure in CRC. CD133Low patients could benefit from adjuvant treatments, while CD133High patients should be given novel treatments besides adjuvant therapy. Our results also provide evidence in support of the CSC hypothesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.